Mass spectrometry combined with transcription sequencing revealed that FGL1 may participate in the EMT process of NSCLC via the PI3K/AKT/HIF-1α pathway, affecting glycolysis molecules such as HIF-1α, PDK1, GLUT1, LDHA, LDHB, and DLDH, as confirmed through in vivo and in vitro experiments. The gene discussed is LDHA; the disease is non-small cell lung carcinoma.